Tempus AI Inc

Tempus AI Inc(TEM)股票分析

$72.220

-5.214 (-7.22%)收盤時

Loading chart…
最高
76.650
開盤
73.260
成交量加權均價
73.24
成交量
10.46M
市值
—
最低
70.840
成交金額
765.86M
企業價值/稅息折舊攤銷前利潤(TTM)
-53.79

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

AI 分析 of Tempus AI Inc (TEM)

買進

Tempus AI Inc is a good buy right now due to its current price of $67.615, which is below the average analyst price target of $80 to $95, indicating significant upside potential. Additionally, the company reported a gross margin of 64.45% in Q2 2026, showing strong profitability potential despite recent losses. However, the main risk is the high short interest of 29.17%, indicating potential volatility if sentiment shifts.

估值指標

Tempus AI Inc(TEM)目前預期本益比為 0.00,5 年平均預期本益比為 -97.78。

預期本益比

高估
5 年均值 P/E
-97.78
目前P/E
0.00
高估
-43.08
低估
-152.47

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
35.13
目前EV/EBITDA
-53.79
高估
1270.14
低估
-1199.89

預期股價營收比

合理
5 年均值 P/S
7.41
目前P/S
7.21
高估
9.54
低估
5.28

持有 TEM 的大戶

L

Lingotto Investment Management LLP

+ 持有TEM

+20.00%

3個月報酬率

A

Allen Holding Inc.

+ 持有TEM

+8.03%

3個月報酬率

A

ARK Investment Management LLC

+ 持有TEM

+7.82%

3個月報酬率

H

H&H International Investment, LLC

+ 持有TEM

+7.40%

3個月報酬率

C

Contrarius Investment Management Ltd.

+ 持有TEM

+2.92%

3個月報酬率

C

Clear Street LLC

+ 持有TEM

-6.16%

3個月報酬率

事件時間軸

2026-10-29 (ET)

15:00:00

Anthropic Files for Nasdaq IPO, Valuation Expected to Exceed $2 Trillion

2026-10-26 (ET)

09:00:00

Tempus AI xR Assay Receives EU IVDR Certification

2026-10-23 (ET)

09:30:00

Pathos AI Announces Strategic Collaboration with Bristol Myers Squibb

09:30:00

Tempus AI Signs Multi-Year Agreement with Bristol Myers Squibb

2026-10-19 (ET)

09:00:00

Tempus AI Announces Results of NSCLC Study

資訊

TEM 常見問題 —— 由 Alphio AI 解答

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. It operates in the Healthcare sector.

Tempus AI Inc is a good buy right now due to its current price of $67.615, which is below the average analyst price target of $80 to $95, indicating significant upside potential. Additionally, the company reported a gross margin of 64.45% in Q2 2026, showing strong profitability potential despite recent losses. However, the main risk is the high short interest of 29.17%, indicating potential volatility if sentiment shifts.

ScalpWalker2026/10/19

$TEM (+3.4% pre) Tempus AI study shows AI pre-screening potential for lung cancer testing

展開
molten_vortex2026/10/18

There is still some time for some names ahead of the $MRNA presentation on Saturday... People will FOMO into these personalized treatment names — not if, but when. $TEM is one of them.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易